Literature DB >> 3755393

Parathyroid hormone-like changes in renal calcium and phosphate reabsorption induced by Leydig cell tumor in thyroparathyroidectomized rats.

R Rizzoli, J Caverzasio, H Fleisch, J P Bonjour.   

Abstract

The Leydig cell tumor Rice H-500 is a model of humoral hypercalcemia of malignancy. Hypercalcemia is considered to result mainly from increased bone resorption. However, a change in renal tubular reabsorption of calcium (Ca) as a contributing factor to the hypercalcemia has not yet been recognized. The purpose of this study was to examine whether the renal handling of Ca was altered in Leydig cell tumor-bearing rats. To avoid counterregulations by Ca-regulating hormones, the effect of the Leydig cell tumor on plasma Ca and phosphate (Pi), urinary Ca and Pi excretion, as well as Ca and Pi renal tubular reabsorptive capacity was investigated in thyroparathyroidectomized rats. Clearance experiments were conducted at a time of tumor development when the glomerular filtration rate was not compromised. Under these conditions, tubular reabsorption of Ca was stimulated, and the maximal tubular reabsorption of Pi was markedly reduced (2.69 +/- 0.27 vs. 4.57 +/- 0.21 mumol/min; P less than 0.001). These changes were accompanied by increased urinary cAMP excretion (77.1 +/- 6.3 vs. 34.7 +/- 2.8 pmol/ml glomerular filtrate; P less than 0.001). These results indicate that the Leydig cell tumor produces a factor with PTH-like activity on the renal tubular reabsorption of Ca and Pi. The increased tubular reabsorption of Ca may play an important role in the pathogenesis of Leydig cell tumor-induced hypercalcemia. This animal model appears to be particularly appropriate for studying the mechanisms of certain types of humoral hypercalcemia of malignancy, as some cancer patients display a change in the renal handling of Ca similar to that observed in primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755393     DOI: 10.1210/endo-119-3-1004

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

Review 1.  Assessment of renal and skeletal components of hypercalcemia.

Authors:  D J Hosking
Journal:  Calcif Tissue Int       Date:  1990       Impact factor: 4.333

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  The Walker 256/B carcinosarcoma in thyroparathyroidectomized rats: a model to evaluate inhibitors of bone resorption.

Authors:  R Rizzoli; H Fleisch
Journal:  Calcif Tissue Int       Date:  1987-10       Impact factor: 4.333

4.  In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice.

Authors:  E C Weir; K L Insogna; D G Brownstein; N H Bander; A E Broadus
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

5.  Adenylate cyclase-stimulating, bone-resorbing and B TGF-like activities in canine apocrine cell adenocarcinoma of the anal sac.

Authors:  E C Weir; M Centrella; R E Matus; M L Brooks; T Wu; K L Insogna
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

Review 6.  Parathyroid hormone-related protein and calcium phosphate metabolism.

Authors:  F Law; S Ferrari; R Rizzoli; J P Bonjour
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.